Ignite Creation Date:
2024-05-06 @ 10:02 AM
Last Modification Date:
2024-10-26 @ 12:23 PM
Study NCT ID:
NCT03146247
Status:
WITHDRAWN
Last Update Posted:
2019-04-18
First Post:
2017-05-05
Brief Title:
Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients
Sponsor:
Diamant Thaci
Organization:
University of Luebeck
Study Overview
Official Title:
Analysis of the Pathogenesis of Itch in Response to Apremilast Therapy in Psoriasis Patients
Status:
WITHDRAWN
Status Verified Date:
2019-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
recruitment was not started
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
Itch
Brief Summary:
This study aims to identify and describe the presence of itch active molecules in psoriasis and response to treatment with apremilast This data will be complemented by immunohistochemical data determining nerve ending density and neuropeptide concentrations before and during treatment and correlated with patient reported outcome It is important to underscore that itch may interfere with various aspects of patient functioning emotions and social status and should therefore be adequately addressed while treating patients with psoriasis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2016-002432-32 | EUDRACT_NUMBER | None | None |